ストックスクリーナーアプリを入手
13.17
2.74%
-0.3795
前日終値:
$13.55
開ける：
$13.45
24時間の取引高:
284.64K
Relative Volume:
0.36
時価総額：
$1.04B
収益：
-
当期純損益:
$-209.96M
株価収益率:
-4.4345
EPS:
-2.97
ネットキャッシュフロー:
$-176.27M
1週間 パフォーマンス:
-8.35%
1か月 パフォーマンス:
+10.75%
6か月 パフォーマンス:
+142.27%
1年 パフォーマンス:
+12.55%
1日の値動き範囲:
$13.02
$13.60
1週間の範囲:
$13.02
$14.64
52週間の値動き範囲:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
REPL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
13.20 | 1.04B | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.18 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.50 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
612.46 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.71 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.01 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Baker BROS. Advisors LP Has $121.06 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Algert Global LLC Has $469,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Braidwell LP Has $33.66 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Group Announces Pricing of Public Offering - Defense World
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch - Seeking Alpha
Replimune Group Amends Sales Agreement with Leerink Partners LLC - Defense World
Replimune reduces offering size in amended sales agreement - Investing.com
Replimune reduces offering size in amended sales agreement By Investing.com - Investing.com Australia
SEC Form 424B5 filed by Replimune Group Inc. - Quantisnow
Cancer firm Replimune readies $125 million offering - The Pharma Letter
REPLReplimune Group, Inc. Latest Stock News & Market Updates - StockTitan
Replimune announces $125 million public offering By Investing.com - Investing.com South Africa
Replimune's SWOT analysis: stock outlook as RP1 nears key milestones By Investing.com - Investing.com Canada
Replimune Announces Pricing of Upsized Public Offering - The Manila Times
Replimune Prices $140M Upsized Public Offering of Common Stock & Warrants | REPL Stock News - StockTitan
Replimune Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.
Replimune's SWOT analysis: stock outlook as RP1 nears key milestones - Investing.com
How to Take Advantage of moves in (REPL) - Stock Traders Daily
Replimune announces $125 million public offering - Investing.com India
Replimune Announces Proposed Public Offering - The Manila Times
Replimune Announces $125M Public Stock Offering, Plans Additional Securities Option | MOBX Stock News - StockTitan
Canadian Dollar/Japanese Yen (CADJPY) QuotePress Release - The Globe and Mail
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright - Defense World
Replimune's stock surges 19% after-hours on FDA BLA submission - MSN
Replimune Group (NASDAQ:REPL) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
BMO Capital Markets Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug - Yahoo Finance
Replimune stock target lifted, outperform on BLA submission By Investing.com - Investing.com UK
Replimune Group (NASDAQ:REPL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Replimune stock climbs after updates on RP1 (REPL:NASDAQ) - Seeking Alpha
Replimune's stock surges 19% after-hours on FDA BLA submission By Investing.com - Investing.com Canada
Replimune seeks FDA approval for melanoma treatment By Investing.com - Investing.com Canada
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
After-Hour Trading Boosts Replimune (REPL) Amid Regulatory Success - Stocks Telegraph
Replimune Group Advances Cancer Treatment with FDA Submission - TipRanks
Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment - MarketWatch
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - The Manila Times
Replimune seeks FDA approval for melanoma treatment - Investing.com
Replimune Seeks FDA Approval for Breakthrough Melanoma Treatment RP1 | REPL Stock News - StockTitan
Replimune's chief commercial officer sells $56,131 in stock By Investing.com - Investing.com Nigeria
Replimune group's chief medical officer sells shares worth $78,111 By Investing.com - Investing.com Canada
Replimune group's chief medical officer sells shares worth $78,111 - Investing.com India
REPL (Replimune Group) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP - MarketBeat
Replimune's chief commercial officer sells $56,131 in stock - Investing.com
Replimune Group Q3 EPS Forecast Decreased by Leerink Partnrs - Defense World
What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat
HC Wainwright Predicts Stronger Earnings for Replimune Group - MarketBeat
Leerink Partnrs Weighs in on Replimune Group Q3 Earnings - MarketBeat
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
0.89%
0.68%
大文字化:
|
ボリューム (24 時間):